Skip to main content

Food Allergy News and Research

Why It's Important to Carry Epinephrine With You Everywhere You Go When You Have Food Allergies

May is National Asthma and Allergy Awareness Month . May 10-16, 2020, is Food Allergy Awareness Week. The Asthma and Allergy Foundation of America (AAFA) and MedicAlert have teamed up to help you manage your child’s food allergies and prevent severe allergic reactions. (Kids With Food Allergies is a division of AAFA). We’re asking you to “ACT” to manage your child’s allergies: “A” means have an action plan for anaphylaxis. “C” reminds you to carry important medicines and have your child wear...

How an Action Plan Can Help You Treat Anaphylaxis

May is National Asthma and Allergy Awareness Month . May 10-16, 2020, is Food Allergy Awareness Week. The Asthma and Allergy Foundation of America (AAFA) and MedicAlert have teamed up to help you manage your child’s food allergies and prevent severe allergic reactions. (Kids With Food Allergies is a division of AAFA). We’re asking you to “ACT” to manage your child’s allergies: “A” means have an action plan for anaphylaxis. “C” reminds you to carry important medicines and have your child wear...

Breaking News: FDA Approves Palforzia, a Ground-Breaking Peanut Allergy Oral Immunotherapy Treatment

On Jan. 31, 2020, the U.S. Food and Drug Administration (FDA) announced its approval of Aimmune Therapeutics’ peanut treatment, Palforzia, for children ages 4 to 17. This is big news for the food allergy community. Food allergies put a significant mental, social and financial burden on families. Until now, strict avoidance has been the only way to avoid allergic reactions. Palforzia may give many families managing peanut allergies more freedom and greater quality of life.

AAFA Brings Patient Voice to FDA Committee Review on Palforzia, Oral Immunotherapy Treatment for Peanut Allergy

On Sept. 13, 2019, the U.S. Food and Drug Administration’s (FDA) Allergenic Products Advisory Committee recommended the approval of Aimmune Therapeutics’ peanut treatment, Palforzia. If approved, Palforzia would be ground-breaking for the future of food allergy treatments. What Is Palforzia? Palforzia, also known as AR101, is a type of oral immunotherapy (OIT) for peanut allergy. If approved, it would be the first FDA-approved treatment for peanut allergy. Currently, some allergists already...

Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut Allergy Treatments

The Asthma and Allergy Foundation of America (AAFA) addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy.

FDA Extends Expiration Dates of All Lots of EpiPens® and Authorized Generic

As supply interruptions and shortages of epinephrine auto-injectors continue, the FDA has extended the expiration dates of all lots of EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors and its authorized generic version currently on the market in the U.S. after a review of stability data. Read more for the new expiration dates.

Help Others See Beyond Food Allergies During National Asthma and Allergy Awareness Month and Food Allergy Awareness Week

Each May since 1984, the Asthma and Allergy Foundation of America (AAFA) has declared May to be National Asthma and Allergy Awareness Month. This month is dedicated to teaching others about asthma and allergies to create more awareness and understanding. Kids With Food Allergies (KFA) is a division of AAFA. May 12-18, 2019, is also Food Allergy Awareness Week. During this week, we focus on spreading information about what it’s like to manage food allergies and raise awareness about anaphylaxis,

FDA Approves First Generic Competitor of EpiPen Epinephrine Auto-Injector

The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.

Updated Mylan Statement on U.S. Supply of EpiPen Auto-Injectors

[PRESS RELEASE] Our manufacturing partner Meridian Medical Technologies, a Pfizer company, continues to experience interruptions in the production of EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors. Over the past few months, there has been intermittent supply of EpiPen at wholesalers and pharmacies. We are actively exploring several options with Pfizer that would help stabilize supply.

What To Do If You Have Trouble Filling Your EpiPen® or Generic Epinephrine Prescription

UPDATE – What we know as of June 6, 2019: ♦ The FDA has extended the expiration dates of all lots of 0.3mg EpiPens® to help with the production delays and shortage. See new expiration dates. ♦ Mylan, distributor of EpiPen®, issued a new statement about the status of their supplies of epinephrine auto-injectors . If you are having trouble getting your EpiPen® prescription filled, you can call Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies . Mylan...

Post
Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
1235 South Clark Street Suite 305, Arlington, VA 22202
Phone: 1-800-7-ASTHMA (1.800.727.8462)
-->
×
×
×
×